These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

628 related articles for article (PubMed ID: 15516966)

  • 1. Retroviral restriction by APOBEC proteins.
    Harris RS; Liddament MT
    Nat Rev Immunol; 2004 Nov; 4(11):868-77. PubMed ID: 15516966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. APOBEC deaminases as cellular antiviral factors: a novel natural host defense mechanism.
    Franca R; Spadari S; Maga G
    Med Sci Monit; 2006 May; 12(5):RA92-8. PubMed ID: 16641889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G.
    Conticello SG; Harris RS; Neuberger MS
    Curr Biol; 2003 Nov; 13(22):2009-13. PubMed ID: 14614829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.
    Mangeat B; Turelli P; Caron G; Friedli M; Perrin L; Trono D
    Nature; 2003 Jul; 424(6944):99-103. PubMed ID: 12808466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. APOBEC-mediated editing of viral RNA.
    Bishop KN; Holmes RK; Sheehy AM; Malim MH
    Science; 2004 Jul; 305(5684):645. PubMed ID: 15286366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. APOBEC-mediated viral restriction: not simply editing?
    Holmes RK; Malim MH; Bishop KN
    Trends Biochem Sci; 2007 Mar; 32(3):118-28. PubMed ID: 17303427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ubiquitination of APOBEC3 proteins by the Vif-Cullin5-ElonginB-ElonginC complex.
    Shirakawa K; Takaori-Kondo A; Kobayashi M; Tomonaga M; Izumi T; Fukunaga K; Sasada A; Abudu A; Miyauchi Y; Akari H; Iwai K; Uchiyama T
    Virology; 2006 Jan; 344(2):263-6. PubMed ID: 16303161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virology. Weapons of mutational destruction.
    KewalRamani VN; Coffin JM
    Science; 2003 Aug; 301(5635):923-5. PubMed ID: 12920286
    [No Abstract]   [Full Text] [Related]  

  • 9. HIV-1 Vif protein blocks the cytidine deaminase activity of B-cell specific AID in E. coli by a similar mechanism of action.
    Santa-Marta M; Aires da Silva F; Fonseca AM; Rato S; Goncalves J
    Mol Immunol; 2007 Jan; 44(4):583-90. PubMed ID: 16580072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retroviruses under editing crossfire: a second member of the human APOBEC3 family is a Vif-blockable innate antiretroviral factor.
    Trono D
    EMBO Rep; 2004 Jul; 5(7):679-80. PubMed ID: 15229643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [HIV-1, a very Vif virus].
    Schwartz O
    Med Sci (Paris); 2004 Feb; 20(2):139-41. PubMed ID: 14997428
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparison of the differential context-dependence of DNA deamination by APOBEC enzymes: correlation with mutation spectra in vivo.
    Beale RC; Petersen-Mahrt SK; Watt IN; Harris RS; Rada C; Neuberger MS
    J Mol Biol; 2004 Mar; 337(3):585-96. PubMed ID: 15019779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Death by deamination: a novel host restriction system for HIV-1.
    Goff SP
    Cell; 2003 Aug; 114(3):281-3. PubMed ID: 12914693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G.
    Sawyer SL; Emerman M; Malik HS
    PLoS Biol; 2004 Sep; 2(9):E275. PubMed ID: 15269786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent insights into HIV-1 Vif.
    Navarro F; Landau NR
    Curr Opin Immunol; 2004 Aug; 16(4):477-82. PubMed ID: 15245742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytidine deamination and resistance to retroviral infection: towards a structural understanding of the APOBEC proteins.
    Huthoff H; Malim MH
    Virology; 2005 Apr; 334(2):147-53. PubMed ID: 15780864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion.
    Xu H; Svarovskaia ES; Barr R; Zhang Y; Khan MA; Strebel K; Pathak VK
    Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5652-7. PubMed ID: 15054139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. APOBEC-mediated interference with hepadnavirus production.
    Rösler C; Köck J; Kann M; Malim MH; Blum HE; Baumert TF; von Weizsäcker F
    Hepatology; 2005 Aug; 42(2):301-9. PubMed ID: 16025511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif.
    Sheehy AM; Gaddis NC; Malim MH
    Nat Med; 2003 Nov; 9(11):1404-7. PubMed ID: 14528300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New insights into the role of Vif in HIV-1 replication.
    Schröfelbauer B; Yu Q; Landau NR
    AIDS Rev; 2004; 6(1):34-9. PubMed ID: 15168739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.